Citius Pharmaceuticals Inc logo

Citius Pharmaceuticals Inc

FRA:47N0 (USA)  
€ 3.29 (0%) Dec 20
At Loss
P/B:
0.28
Market Cap:
€ 21.56M ($ 22.47M)
Enterprise V:
€ 5.27M ($ 5.50M)
Volume:
-
Avg Vol (2M):
1.63K
Trade In:

Business Description

Description
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Name Current Vs Industry Vs History
Cash-To-Debt 55.97
Equity-to-Asset 0.88
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 17.54
9-Day RSI 25.16
14-Day RSI 28.9
6-1 Month Momentum % -76.81
12-1 Month Momentum % -80.43

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.75
Quick Ratio 6.75
Cash Ratio 4.31

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -41.9
Shareholder Yield % 0.8

Profitability Rank

Name Current Vs Industry Vs History
ROE % -43.68
ROA % -38.35
ROIC % -55.85
ROC (Joel Greenblatt) % -1008.6
ROCE % -43.35

Financials (Next Earnings Date:2025-02-14 Est.)

FRA:47N0's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Citius Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -5.559
Beta 0.71
Volatility % 96.98
14-Day RSI 28.9
14-Day ATR (€) 0.136568
20-Day SMA (€) 3.29
12-1 Month Momentum % -80.43
52-Week Range (€) 3.1225 - 23.325
Shares Outstanding (Mil) 7.73

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Citius Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Citius Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Citius Pharmaceuticals Inc Frequently Asked Questions

What is Citius Pharmaceuticals Inc(FRA:47N0)'s stock price today?
The current price of FRA:47N0 is €3.29. The 52 week high of FRA:47N0 is €23.33 and 52 week low is €3.12.
When is next earnings date of Citius Pharmaceuticals Inc(FRA:47N0)?
The next earnings date of Citius Pharmaceuticals Inc(FRA:47N0) is 2025-02-14 Est..
Does Citius Pharmaceuticals Inc(FRA:47N0) pay dividends? If so, how much?
Citius Pharmaceuticals Inc(FRA:47N0) does not pay dividend.

Press Release

Subject Date
No Press Release